Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study Cohort 2 included 38 patients (61% male; median age 72.5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback